Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv

Testing a immunological drug as a new treatment for early type 1 diabetes

26 January, 2023

CLINICAL STUDY. A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1 diabetes. The theory is that the drug could preserve the patient’s remaining insulin production.

A large number of hospitals throughout Sweden are participating in this large project, which is funded by the Swedish Research Council within clinical treatment research. The project is headed by Marcus Lind, a professor of diabetology at the University of Gothenburg and chief physician responsible for clinical diabetes research at Sahlgrenska University Hospital/Östra Hospital and NU-hospital Group.

Marcus Lind. Photo: Anette Juhlin.

Lind notes that the study could mean a big change in how type 1 diabetes is treated: “Of the mechanisms now being investigated for immunological treatment of type 1 diabetes, I have the greatest confidence in this one, but I am well aware of how difficult success will be.”

An immunological disease

Type 1 diabetes is one of the most common chronic diseases in children, but the disease can also develop in adults. In the disease, the body’s own immune response destroys beta cells in the pancreas so that the body can no longer produce insulin. People with type 1 diabetes need to take insulin injections or use an insulin pump and strictly tract their blood sugar levels for the rest of their lives, which requires a lot of effort.

The beta cells die slowly, so everyone with newly developed type 1 diabetes continues to produce insulin during the first years of the disease.

“They benefit greatly from the remaining insulin their body produces. If they could just maintain this production, treating type 1 diabetes would be much easier. So far, we have not had a good treatment for preventing beta cell death, but we have reason to believe that a medication currently approved for individuals with psoriasis could have a protective effect for individuals with type 1 diabetes,” says Marcus Lind.

PhD student and diabetes nurse Arndís Ólafsdóttir in discussion with Marcus Lind, who is one of her supervisors. In her thesis project, she leads a randomized Norwegian-Swedish multicenter study. The project evaluates the effect of systematic intensive therapy. In the study, glucose data is sent electronically from patients with type 1 diabetes using a sensor under the skin for regular support about insulin dosages and other measures to stabilize blood sugar in the everyday life of patients with type 1 diabetes. The study includes approximately 120 patients in Sweden and Norway.

Tests show the two stages of the disease

Based on immunological patterns in the blood, currently researchers can determine with a high probability who will develop type 1 diabetes (stage 1 of type 1 diabetes) within a few years. About a year before the onset of the disease, they can then see disturbances in the blood sugar pattern with stress tests, even if criteria for diabetes are not met (stage 2 of the disease). When clinical onset occurs, it is classified as stage 3.

“If we succeed in identifying the immunological mechanism that is central to the destruction of beta cells, we will also be able to screen children and adults in the future and treat them even before the onset of the disease. The disease will then be prevented from breaking out or counteracted so that it does not begin until much later in life.”

Psoriasis and type 1 diabetes

The drug to be tested affects the immune response in the body by inhibiting the protein interleukin-17, which seems to be an important signaling molecule in the process that destroys beta cells. For the last few years, the drug has been used as a treatment for psoriasis, where a specific type of white blood cells, known as TRM cells, plays a key role in development of the disease, just as these cells seem to do in type 1 diabetes. Among other things, these cells act through IL-17, which the current treatment affects.

“In fact, research on type 1 diabetes and IL-17 has been going on for almost 20 years. Animal experiments have shown that stimulation of this signaling pathway accelerates the development of type 1 diabetes. Other studies have shown that this signaling pathway is usually overactivated in people with type 1 diabetes. It will be particularly interesting to evaluate for the first time whether the treatment can protect insulin-producing cells in the pancreas, in light of recent research on TRM cells in newly diagnosed type 1 diabetes, just as in psoriasis.”

Recruitment of individuals with type 1 diabetes for a comprehensive multicenter study has now begun. The study will include adults, between ages 18 and 35, who have been diagnosed with type 1 diabetes in the last three months, where a blood test has shown that they have an ongoing immunological process affecting the beta cells. A total of 127 individuals will be included, with half being randomly assigned to receive IL-17 inhibitors and half receiving a placebo in the control group.

Towards precision medicine

In parallel with the Swedish study now being conducted from the University of Gothenburg, several other studies are underway elsewhere in the world. They are also seeking ways to treat the immunological cause behind type 1 diabetes and not just the symptoms, which until now has been the only treatment option.

As with many other diseases, researchers of type 1 diabetes are now on the verge of precision medicine. Efforts to map different subgroups within type 1 diabetes have just begun to study, for example, a certain gene variation that causes a certain type of islet cell antibodies to first appear.

“It is likely that treatment with IL-17 inhibitors may be more effective for certain subgroups. If the results from our study are encouraging, over time we can investigate certain immunological patterns or cell types in the blood that can be used to identify patient groups that respond best to the treatment.”

BY: ELIN LINDSTRÖM

By: Elin Lindström
Tagged With: institutionen för medicin, Vetenskapsrådet

Add your own events in the Akademiliv Calendar

December 13 – LUCIA PROCESSION

Gothenburg’s Medicinska Sångarcorps Corus Acusticus performs Lucia songs at Sahlgrenska Academy.

  • 12:30 start at Häloscaféet, Hälsvetarbacken
  • 12:45 end at Salt&Syra / Natrium

This year’s winter break is approaching. This year, Akademiliv’s newsletter will be paused from December 21 to January 9.

Vanessa Vermeirssen: Inferring regulatory programs of tumor heterogeneity

Hybrid meeting – in Lecture Hall Arvid Carlsson or online via Zoom.
NOTE the time: 1300H.

  • Hybrid webinar 13:00-14:00, Thursday November 16th.
  • Link to Zoom webinar.
  • Sahlgrenska Academy Science Seminars – see full program in the Staff Portal.

Information from Sahlgrenska Academy Research Support Office

[UPDATED NOVEMBER 2023]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated on a monthly basis.
Current and previous newsletters are also available in the Staff Portal.

’20 minutes for researchers’ is back – see full autumn program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

More news

VR funds national postgraduate school in compulsory psychiatric care and forensic psychiatry

8 December, 2023

POSTGRADUATE STUDIES. A new national postgraduate school in compulsory psychiatric care and forensic psychiatry is now being established by the …  

Win a copy of Ingmar Skoog’s acclaimed book (in Swedish)

8 December, 2023

BOOK. “70 is the new 50” has become a common phrase. The author Ingmar Skoog has now written a book on the subject with this very title. Sah …  

Challenging beliefs about person-centered care with humor and evidence in dialogue material

8 December, 2023

RESEARCH COMMUNICATION. Using humor as a tool, researchers hope to find new ways to make knowledge for the development of healthcare easier to …  

Doctoral thesis: Fear’s impact post Achilles tendon rupture

7 December, 2023

DOCTORAL THESIS. Achilles tendon rupture is a common injury, with about 20 percent of individuals unable to return to their previous level of …  

Podden Akademiliv – about fibromyalgia and other long-term generalized pain (in Swedish)

28 November, 2023

RESEARCH COMMUNICATION. In the latest episode of the Akademiliv podcast (in Swedish), you will hear Anna Grimby Ekman, professor of health …  

Doctoral thesis on predicting and preventing preterm delivery

28 November, 2023

DOCTORAL THESIS. Preterm delivery is the leading cause of death in children under the age of five. Tove Wikström’s research focuses on methods to …  

Two of this year’s Nobel Laureates in physics will lecture at Chalmers in December – registration required

23 November, 2023

NOBEL. Two of this year's three Nobel laureates in physics (Anne L´Hullier and Ferenc Krausz) will visit the University of Gothenburg and …  

The central theme for this year’s Research Day: common diseases (conference in Swedish)

23 November, 2023

INTERACTION. Research that saves lives – from screening to rehabilitation. That is the theme for the upcoming edition of Research Day, held in S …  

Davide Angeletti studies differentiation of B-celler

23 November, 2023

SCIENTIST PORTRAIT. Davide Angeletti is an associate senior lecturer at the Institute of Biomedicine, University of Gothenburg. Davide´s work …  

Significantly lower risk of Post-COVID Condition among vaccinated people

23 November, 2023

NEW STUDY. People who have been vaccinated against COVID-19 have a significantly lower risk of being diagnosed with Post-COVID Condition after …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen